Aprepitant clinical trials
Aprepitant is named as an intervention in 5 current clinical trials in our Canada and China registers. 2 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Hubei Cancer Hospital (1). The most-studied condition is Nausea With Vomiting Chemotherapy-Induced.
Where Aprepitant is approved
All regulators →Of the three regulators tracked here, the first to approve Aprepitant was the US, on 26 Mar 2003. It is approved in 3 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Aprepitant patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Aprepitant, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 15 listed patents; the last listed expires 18 Sep 2035 (US 9808465).
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
What health systems spend on Aprepitant
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Aprepitant works
All drug targets →- Neurokinin 1 receptor antagonist AntagonistTarget: TACR1 tachykinin receptor 1✓ In ChEMBL and the Guide to Pharmacology
- COVID-19Phase 3
- DysmenorrheaPhase 3
- PruritusPhase 3
- Myeloproliferative disorderPhase 3
- Parkinson diseasePhase 2
- Alcohol dependencePhase 2
- Cannabis dependencePhase 2
- Diabetes mellitusPhase 2
- Hypertensive disorderPhase 2
- Non-small cell lung carcinomaPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1471, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 3490, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Aprepitant
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 6 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: EmendEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Aprepitant
- ATC code
- A04AD12
- ChEMBL
- CHEMBL1471
- DrugBank
- DB00673
- PubChem CID
- 135413536
- CAS number
- 170729-80-3
- FDA UNII
- 1NF15YR6UY
- Wikidata
- Q621834
- Wikipedia
- Aprepitant
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Aprepitant
5 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Aprepitant across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
6 single-substance products containing Aprepitant on the HPRA medicines list.
- Aprepitant Accord 125 mg hard capsulesAccord Healthcare Ireland Ltd. · PA2315/148/002 · Marketed
- Aprepitant Accord 80 mg hard capsulesAccord Healthcare Ireland Ltd. · PA2315/148/001 · Marketed
- EMEND 125 mg hard capsulesMerck Sharp & Dohme BV, · EU/1/03/262/004-005
- EMEND 125 mg hard capsules EMEND 80 mg hard capsulesMerck Sharp & Dohme BV, · EU/1/03/262/006
- EMEND 80 mg hard capsulesMerck Sharp & Dohme BV, · EU/1/03/262/001-003
Supply shortages
- Aprepitant Oral Powder for SuspensionUS (FDA) · Resolved · updated 8 Apr 2026
- Aprepitant Zentiva 80 mg und 125 mg HartkapselnGermany (BfArM) · Production problem · 1 Oct 2025 to 30 Apr 2027
- Aprepitant STADA 125 mg HartkapselnGermany (BfArM) · Production problem · 17 Feb 2025 to 14 Dec 2026
- Aprepitant STADA 125 mg und 80 mg HartkapselnGermany (BfArM) · Production problem · 5 Aug 2024 to 14 Dec 2026
- Aprepitant AL 125 mg und 80 mg HartkapselnGermany (BfArM) · Other reason · 1 Sep 2025 to 31 Dec 2026
- Aprepitant AL 125 mg HartkapselnGermany (BfArM) · Other reason · 1 Aug 2024 to 8 Dec 2026
- Aprepitant AL 80 mg HartkapselnGermany (BfArM) · Other reason · 1 Nov 2024 to 11 Dec 2026
Conditions studied with Aprepitant
8 conditionsSponsors
lead sponsor per trialBy country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 3 | 1 |
| Clinical trials in China | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Aprepitant trials
How many clinical trials are testing Aprepitant?
5 current trials in our Canada and China registers name Aprepitant as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Aprepitant trials recruiting patients?
Yes. 2 of the 5 trials are recruiting: 1 with sites in Canada and 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Aprepitant clinical trials?
Hubei Cancer Hospital (1), Second Affiliated Hospital, Zhejiang University, School of Medicine (1), Ottawa Hospital Research Institute (1) and IWK Health Centre (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Is Aprepitant licensed in Ireland?
Yes. The HPRA medicines list includes 6 single-substance products containing Aprepitant, for example Aprepitant Accord 125 mg hard capsules (Accord Healthcare Ireland Ltd.). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Aprepitant shortage?
The registers we track list 7 entries for Aprepitant: US FDA: resolved; 6 German notices. Shortages are product- and country-specific; check with a pharmacist.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Aprepitant works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Aprepitant works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Aprepitant (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.